Did Trevena get FDA approval?
The U.S. Food and Drug Administration (FDA) approved a new intravenous opioid for short term management of acute pain in a hospital setting, Trevena’s Olinvyk. Olinvyk is indicated for short-term intravenous use in hospitals or other controlled clinical settings, such as during inpatient and outpatient procedures.
What does Trevena Inc do?
Trevena, Inc. (NASDAQ: TRVN) is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with central nervous system (CNS) disorders.
When did Olinvyk get approved?
Oliceridine was approved for medical use in the United States in August 2020. The FDA granted approval of Olinvyk to Trevena Inc. The DEA issued an interim final rule on October 30, 2020 designating oliceridine as CSA Schedule II (DEA Code 9245).
Is Oliceridine an opioid?
Today, the U.S. Food and Drug Administration approved Olinvyk (oliceridine), an opioid agonist for the management of moderate to severe acute pain in adults, where the pain is severe enough to require an intravenous opioid and for whom alternative treatments are inadequate.
When did Trevena go public?
Trevena’s initial public offering was on January 30, 2014.
Is Pfizer buying Trevena?
Upon Trevena’s receipt of all necessary Regulatory Approvals pursuant to the terms and conditions of this Agreement and for the term of this Agreement, Pfizer shall manufacture, sell and deliver to Trevena and Trevena will purchase from Pfizer certain of its requirements for the Product for sale in the Territory at the …
What does Trevena mean?
The name Trevena is a girl’s name meaning “village on a mountain”. The original Cornish name for the town better known today as Tintagel. With its Arthurian heritage, this makes a good choice for those fond of the legends of Lancelot, Guinevere and King Arthur.
When was Tecartus FDA approved?
On October 1, 2021, the FDA approved brexucabtagene autoleucel (brand name Tecartus) for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
What is TRV027?
About TRV027 Trevena is developing TRV027, a novel AT1 receptor selective agonist designed with Nobel Prize winning technology, as a potential treatment for acute respiratory distress syndrome (ARDS) and abnormal clotting for COVID-19 patients.
Can opioids be administered IV?
Opioid medications are used widely for control of acute and chronic pain in hospitalized medical patients. While effective for analgesia, opioid administration via the intravenous route carries an increased risk of adverse effects, such as euphoria, nausea, and hypotension, compared with oral administration.